Clustered Regularly Interspaced Short Palindromic Repeats

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

2 days ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%

Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool

2 weeks ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PGI, Retrotransposons, Technology

PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats

Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy

1 month ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Infrequent, Liver diseases, Primary hyperoxaluria, type I

Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding

Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Cancer Vaccines, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Discovery, Gene Modification, Investments, personalized therapies, Platform technologies, Precision Medicine, solid-state batteries

CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation

NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease

3 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, Clustered Regularly Interspaced Short Palindromic Repeats, England, exagamglogene autotemcel, gene therapy, Nance-Horan syndrome, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution

Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

4 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

4 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

4 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology